Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody

Clinical Cancer Research

Volumn 2, Issue 8, 1996, Pages 1289-1297

  Deb, Nimisha ^b   Goris, Michael ^a   Trisler, Kirk ^a   Fowler, Sherry ^a   Saal, Jeannette ^a   Ning, Shoucheng ^a   Becker, Mark ^c   Marquez, Carol ^d   Knox, Susan ^a,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST LUKE S HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; MONOCLONAL ANTIBODY Y 90; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DOSE CALCULATION; DOSE RESPONSE; DRUG DISTRIBUTION; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; MALE; MICE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION;

EID: 0029737680     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Wingo, P. A., Tong, T., and Bolden, S Cancer statistics, 1995. CA Cancer J. Clin., 45: 8-30, 1995.
2. Catalona, W. J., Smith, D. S , Ratliff, T. L., and Basler, J W. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. J Am. Med. Assn., 270: 948-954, 1993.
3. Oesterling, J. E., Suman, V. J., Zincke, H., and Bostwick, D. G. PSA-detected (clinical stage Tlc or B0) prostate cancer: pathologically significant tumors. Urol. Clin. North Am., 20: 687-693, 1993.
4. Hanks, S. E., Myers, O. E., and Scardino, P. T. Cancer of the Prostate. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 1073-1077. Philadelphia: J. B. Lippincott Co., 1993.
5. Scott, W. W., Menon, M., and Walsh, P. C. Hormonal therapy of prostatic cancer. Cancer (Phila.), 45: 1929-1936, 1980.
6. Griffiths, K., Eaton, C L., Harper, M. E., Turkes, A., and Peeling, W. B. Hormonal treatment of advanced disease: some newer aspects. Semin. Oncol., 21: 672-687, 1994.
7. Labrie, F., Dupont, A., and Belanger, A. Complete androgen blockade for the treatment of prostate cancer. In: V. T. DeVita, S. Hellman, and S. H. Rosenberg (eds.), Important Advances in Oncology, pp. 193-217. Philadelphia: J. B. Lippincott Co., 1985.
8. Bander, N. H. Current status of monoclonal antibodies for imaging and therapy of prostate cancer. Semin. Oncol., 21: 607-612, 1994.
9. Denis, L. J. Controversies in the management of localized and metastatic prostatic cancer. Eur. J. Cancer. 27: 333-341, 1991.
10. Resnick, M. I., and Grayhack, J. T. Treatment of stage IV carcinoma of the prostate. Urol. Clin. North Am., 2: 141-161, 1975.
11. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989
12. Scher, H. I., Curley, T., Yeh, S., Iversen, J. M., O'Dell, M., and Larson, S. M. Therapeutic alternatives for hormone-refractory prostatic cancer. Semin. Urol., 10: 55-64, 1992.
13. Kuban, D. A., Schellhammer, P. F., and el-Mahdi, A. M. Hemibody irradiation in advanced prostatic carcinoma. Urol. Clin. North Am., 18: 131-137, 1991.
14. Eisenberger, M. A. Chemotherapy for prostate carcinoma. NCI Monogr., 7: 151-163, 1988.
15. Petrylak, D. P., Scher, H. I., Li, Z., Myers, C. E., and Geller, N. L. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer (Phila.), 70: 2870-2878, 1992.
16. Goldenberg, D. M. New developments in monoclonal antibodies for cancer detection and therapy. CA Cancer J. Clin., 44: 43-64, 1994.
17. Knox, S. Radioimmunotherapy of non-Hodgkin's lymphoma. Semin. Radiat. Oncol., 5: 331-341, 1995.
18. Borden, E. C., and Anderson, T. Adenocarcinomas. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.). Biologic Therapy of Cancer, pp. 590-595. Philadelphia: J. B. Lippincott Co., 1995.
19. Larson, S. M., Sgouros, G., and Cheung, N. V. Radioisotope conjugates In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer, pp., 530-551. Philadelphia: J. B. Lippincott Co., 1995.
20. Meredith, R. F , and Buchsbaum, D. J. Radioimmunotherapy of solid tumors. In: R. E. Henkin (ed.), Nuclear Medicine: Principles and Practice, pp. 601-608. St. Louis: Mosby Publishers, 1995.
21. Pastan, I., Lovelace, E., Rutherford, A. V., Kunwar, S., Willingham, M. C., and Peehl, D. M. PRI: a monoclonal antibody that reacts with an antigen on the surface of normal and malignant prostate cells. J Natl. Cancer Inst., 85: 1149-1154, 1993.
22. Babaian, R. J., and Lamki, L. M. Radioimmunoscintigraphy of prostate cancer. Semin. Nucl. Med., 19: 309-321, 1989.
23. Wright, G. J., Beckett, M. L., Starling, J. J., Schellhammer, P. F., Sieg, S. M., Ladaga, L. E., and Poleskic, S. Immunohistochemical localization of prostate carcinoma-associated antigens. Cancer Res., 43: 5509-5516, 1983.
24. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res., 7: 927-935, 1987.
25. Abdel-Nabi, H., Wright, G. L , Gulfo, J. V., Petrylak, D. P., Neal, C. E , Texter, J. E., Begun, F. P., Tyson, I, Heal, A , Mitchell, E., Purnell, G., and Harwood, S. J. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin. Urol., 10: 45-54, 1992.
26. Meredith, R. F., Khazaeli, M. B., Carabasi, M. H., and LoBuglio, A. F. Radioimmunotherapy of prostate cancer. In: P. Riva (ed.), Therapy of Malignancies with Radioconjugate Monoclonal Antibodies: Present Possibilities and Future Perspectives. Amsterdam: Harwood Academic Publisher, in press, 1996.
27. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Schlom, J., Russell, C. D., Liu, T., and LoBuglio, A. F. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med., 35: 1017-1022, 1994.
28. Abdel-Nabi, H., Spaulding, M., Farrell, E., Derby, L., and Lamonica, D. Treatment of refractory prostate carcinoma with Y-90 KC4. J. Nucl. Med., 36: 213P, 1995.
29. Carabasi, M. H., Meredith, R. F., Marshall, M. E., Khazaeli, M. B., Schlom, J., and LoBuglio, A. F. Basic and clinical aspects of prostate cancer, multimodality therapy with autologous stem cell rescue for hormone-resistant prostate cancer. Proceedings of the AACR Conference on Basic and Clinical Aspects of Prostate Cancer (Abst #C-26), 1994.
30. Hill, T. L., Hinkle, G. H., Olsen, J., Fry, J., More, N., Burgers, J , and Badalament, R. SPECT imaging of prostate carcinoma using a monoclonal antibody (Indium-111-CYT356). J. Nucl. Med., 35: 216P, 1994.
31. 111indium-labeled monoclonal antibody CYT-356. J. Urol., 1952-1955, 1994.
32. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate, 18: 229-241, 1991.
33. Lederer, C., and Shirley, V. Table of Isotopes, 7th ed. New York: John Wiley & Sons, Inc., 1978.
34. 90Y-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res., 2: 457-470, 1996.
35. Herpst, J. M., Klein, J. L., Leichner, P. K., Quadri, S. M., and Vriesendorp, H. M. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J. Clin. Oncol., 13: 2394-2400, 1995.
36. Vriesendorp, H. M., Motion, J. D., and Quadri, S. M. Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res., 55 (Suppl.): 5888s-5892s, 1995.
37. Waldmann, T. A., White, J. D., Carrasquillo, J. A., Reynolds, J. C., Paik, C. H., Gansow, O. A., Brechbiel, M. W., Jaffe, E. S., Fleisher, T. A., Goldman, C. K., Top, L. E., Bamford, R., Zaknoen. S., Roessler, E., Kasten-Sportes, C., England, R., Litou, H., Johnson, J. A., Jackson-White, T., Manns, A., Hanchard, B., Junghaus. R. P , and Nelson. D L. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood, 86: 4063-4075, 1995.
38. 90Y Mx-diethylenetriamine-pentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a Phase I trial. Cancer Res., 55 (Suppl.): 5921s-5924s, 1995.
39. DeNardo, S. J., Kramer, E. L., Richman, C. M., Salako. Q. A., Perez, E. A , O'Grady, L. F., Rippon, M. B., Glenn, S. D., Butchko, G. M., Couto. J. C., Ceriani, R. L., and DeNardo, G. L. Radioimmunotherapy of breast cancer with Y-90/In-111 BrE-3: current clinical results and therapeutic potential. J. Nucl. Med., 34: 53P, 1993.
40. Hird, V., Maraveyas, A., Snook, D., Dhokia, B., Soutter, W. P., Meares, C., Stewart, J. S., Mason, P., Lambert, H. E., and Epenetos, A. A. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br. J. Cancer, 68: 403-406, 1993.
41. 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84 66 in a Phase I radioimmunotherapy trial. Cancer Res., 55 (Suppl.): 5929s-5934s. 1995.
42. Hopkins, K., Chandler, C., Bullimore, J., Sandeman, D., Coakham. H., and Kemshead, J. T. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother. Oncol., 34: 121-131, 1995.
43. Goris, M. L., Knox, S. A., Nielsen, K. R., and Bouillant, O. Organ modeling in the quantitation of planar images for distribution studies. Cancer (Phila.), 73 (Suppl.): 919-922, 1994.
44. 111indium-labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol., 752: 1490-1495, 1994.
45. Knox, S. J. Overview of studies of experimental radioimmunotherapy. Cancer Res., 55 (Suppl.): 5832s-5836s, 1995.